Skip to content

Exploring the Molecular Mechanisms and Clinical Efficacy of Jiuhe Dan in the Treatment of Acute Pancreatitis Based on Network Pharmacology

Exploring the Molecular Mechanisms and Clinical Efficacy of Jiuhe Dan in the Treatment of Acute Pancreatitis Based on Network Pharmacology

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001006
Enrollment
Unknown
Registered
2025-05-18
Start date
2024-06-25
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatitis

Interventions

Control Group:Routine Conventional Therapy
Intervention Group:Standard medical treatment combined with abdominal topical application of Jiuhe Dan

Sponsors

Suining Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1).Meet the diagnostic criteria for acute pancreatitis; 2).Time from disease onset =10 days; 3).Voluntarily signed informed consent form.

Exclusion criteria

Exclusion criteria: 1).Patients with local skin breakdown; 2).Individuals with allergic constitution or hypersensitivity to Jiuhe Dan; 3).Patients with severe comorbidities (e.g. respiratory cardiovascular/cerebrovascular hepatic/renal insufficiency hematologic disorders or psychiatric diseases); 4).Pregnant or lactating women; 5).Use of other topical medications for treatment since the onset of the current episode; 6).Poor compliance or inability to adhere to the prescribed treatment regimen; 7).Incomplete medical data significantly affecting efficacy evaluation; 8).Concurrent pancreatic or biliary tract malignancies.

Design outcomes

Primary

MeasureTime frame
Inflammatory factors:Interleukin-6,High-sensitivity C-reactive protein;

Secondary

MeasureTime frame
Clinical severity assessment:Ranson CriteriaAcute Physiology and Chronic Health Evaluation II etc.;Healthcare utilization metrics:Hospitalization costs,Length of stay, etc.;Systemic complications:Organ failureSystemic Inflammatory Response Syndromeetc.;Local complications:Acute necrotic collectionSplenic vein thrombosisPortal vein thrombosis;Serum Enzymatic Markers:AmylaseLipaseAlanine AminotransferaseLactate Dehydrogenase.;

Countries

China

Contacts

Public ContactLinlin Chen

Suining Central Hospital

chenlinlinmedical@outlook.com18008253646

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026